Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

216.70SEK
17 Oct 2018
Change (% chg)

-1.40kr (-0.64%)
Prev Close
218.10kr
Open
218.00kr
Day's High
223.30kr
Day's Low
216.50kr
Volume
538,984
Avg. Vol
857,226
52-wk High
299.60kr
52-wk Low
107.40kr

Select another date:

Fri, Jul 20 2018

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

Select another date: